Skip to content

ADMA Biologics ADMA Earnings yield

Earnings yield at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-13.6%-4.3pp
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-9.9%-2.8pp
Zymeworks logo
ZymeworksZYME
-5.5%-2.1pp
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
2.2%+1.2pp
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-4.4%-1.5pp
Quest Diagnostics logo
Quest DiagnosticsDGX
4.8%0.0pp

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio+0.4×

Where this comes from

Calculated from ADMA Biologics’s reported figures.

Based on trailing twelve months.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's earnings yield?
ADMA Biologics (ADMA) reported earnings yield of 7.7% in Q1 2026.
How has ADMA Biologics's earnings yield changed year-over-year?
ADMA Biologics's earnings yield increased by 75.7% year-over-year, from 4.4% to 7.7%.
What is the long-term trend for ADMA Biologics's earnings yield?
Over 5 years (2020 to 2025), ADMA Biologics's earnings yield has grown at a -29.8% compound annual growth rate (CAGR), from -19.8% to 3.4%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.